Navigation Links
Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
Date:4/21/2011

BRANFORD, Conn., April 21, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder (PTSD). Ganaxolone modulates inhibitory GABA-A receptors, possibly at a specific neurosteroid recognition site. Neurosteroid levels have been implicated in both the severity and treatment outcome in PTSD patients.

"This trial will test the hypothesis that a neurosteroid analog of allopregnanolone will be beneficial in the treatment of PTSD and augment our existing safety database for ganaxolone in humans," stated Gail Farfel, Ph.D., Chief Development and Regulatory Officer of Marinus. "Achieving full remission of PTSD symptoms is difficult with current treatments for PTSD.  New options that can increase efficacy are needed for the growing population of PTSD patients worldwide."

This randomized, double-blind, placebo-controlled clinical trial is being conducted by the INTRuST Consortium to evaluate the safety, tolerability and efficacy of oral ganaxolone after six weeks of dosing in patients with PTSD. The INTRuST Consortium is a group of clinical study centers in the United States funded by a Department of Defense award to advance treatments and medical research in PTSD and traumatic brain injury. This public-private collaboration will study ganaxolone under Marinus' Investigational New Drug Application (IND) filed with the Food and Drug Administration (FDA). The trial will take place in the United States and is designed to enroll approximately 120 PTSD patients.

"Ganaxolone has been shown in clinical studies to be efficacious and well tolerated in refractory epilepsy patients, and we expect the INTRuST PTSD trial to expand ganaxolone's profile into neurosteroid-mediated psychiatric disorders," said Kenneth Shaw Ph.D., Senior Vi
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marinus Pharmaceuticals Issued Patent for Ganaxolone
2. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Harwood Feffer LLP ... board of directors of PDL BioPharma, Inc. ("PDL" or ... the board has breached its fiduciary duties to shareholders ... September 16, 2014, the Company disclosed: "On September 11, ... accounting firm, Ernst & Young LLP ("EY"), that it ...
(Date:9/19/2014)... 19, 2014 "Copay coupons," a ... of brand drugs among patients with prescription drug coverage, may ... a new report  from the Department of ... General (OIG). Federal anti-kickback laws prohibit suppliers from ... subsidized by the federal government. ...
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... , , GREENSBORO, N.C., Dec. 23 ... four users who allege kidney damage due to the use ... in preparation for a colonoscopy. (Holshouser et al v. ... are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, Ltd., ...
... , , Accelerated approval ... Dec. 23 The U.S. Food and Drug Administration today ... ages 65 years and older to prevent disease caused by ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , People in this age group ...
Cached Medicine Technology:Suits Commenced Against Maker of Prescription Cleansing Drug 2FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older 2FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older 3
(Date:9/21/2014)... Huntington, New York (PRWEB) September 21, 2014 ... release of their Risk Management Portal designed for ... applications with the intent to support effective risk ... is scheduled to go live coinciding with Waldorf’s ... September 21-24, 2014. , These applications were developed ...
(Date:9/21/2014)... PA (PRWEB) September 21, 2014 "I ... boost without having to consume sugary, foul-tasting energy drinks," ... did not always just want to drink plain, old ... alternative energy booster." , He developed ENERG CHEWING GUM ... assist with weight loss. The formula contains nutritious vitamins, ...
(Date:9/21/2014)... cancer cells metastasize? Think of Sparta. , Ancient Greek ... them for the demands of battle on distant fields. ... according to a new study revealing previously unknown differences ... original tumor site, and those that travel to other ... to metastasize is the primary cause of cancer-related death, ...
(Date:9/21/2014)... September 21, 2014 "I want to ... and back but haven’t the money for chiropractors," said ... to have such a product for myself." , The ... to stretch the thigh muscles and align the spine ... as relieves discomfort of pinched nerves. Compact and easy ...
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 ... develops, implements and supports electronic medical records (EMR) ... benefited from federal healthcare legislation during the past ... do so during the five years to 2019. ... Clinical Health Act established Medicare and Medicaid incentives ...
Breaking Medicine News(10 mins):Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4
... in Mumbai suffers from backache, caused mainly by the poor ... out by Health India, a New Delhi-based non-profit group, the ... Delhi and 77 percent in Mumbai who use public transport ... ,"Bad roads, overcrowded public transport systems, poor quality of ...
... On the eve of the World AIDS Day (Dec 1), ... to 20,000 HIV infected children, Health Minister Anbumani Ramadoss said ... launching a scheme to provide free ARV treatment for children ... for the paediatric drugs and three to four pharmaceutical companies ...
... of Secondary Education (CBSE) has taken following measures to ... a joyful //experience:- ,(i) Abolition of homework for ... ,(ii) Interesting and meaningful alternative activities to replace the ... ,(iii) Continuous and Comprehensive Evaluation from class ...
... device's track record in the United Kingdom concluded that ... the technology's use at least// for now. The review ... Assessment, the international journal series of the Health Technology ... Research in the United Kingdom. ,An implantable ...
... The Minister of Tourism and Culture Smt. Ambika Soni ... promoting India as a Global Health Care Destination. ... foreign tourist to the country Ministry of Tourism in ... the following measures to promote Medial Tourism: ,i) ...
... a heart attack indicates future heart problems, according to ... edition of the// Journal of the American College of ... of depression after having a heart attack are at ... to undergo new depression-related screening protocols and treatment strategies. ...
Cached Medicine News:Health News:Public Transport Causing Backaches in Delhi, Mumbai 2Health News:Free HIV Treatment to Be Launched for Children 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 3Health News:Depression After Heart Attack Means More Heart Problems 2Health News:Depression After Heart Attack Means More Heart Problems 3
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
S.O.C. Medium...
Medicine Products: